Persistence of apremilast in moderate-to-severe psoriasis. A real-world analysis of 14,147 apremilast- and methotrexate-naive patients in the French national health insurance database

Psoriasis

Persistence of treatment with conventional systemic agents for patients with psoriasis: a real-world analysis of 73,168 new-users from the French National Health Insurance database (SNDS)

Br J Dermatol.

Bergqvist C, Mezzarobba M, Weil A, Sbidian E

doi: 10.1111/bjd.18734.

Psoriasis

A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL)

J Eur Acad Dermatol Venereol.

Seneschal J, Lacour JP, Bewley A, Faurby M, Paul C, Pellacani G, De Simone C, Horne L, Sohrt A, Augustin M, Hammond E, Reich K

doi: 10.1111/jdv.16568.

Psoriasis

An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Lancet.

Warren RB, Mrowietz U, von Kiedrowski R, Niesmann J, Wilsmann-Theis D, Ghoreschi K, Zschocke I, Falk TM, Blödorn-Schlicht N, Reich K

doi: 10.1016/

Psoriasis

A Comparison of Psoriasis Severity in Pediatric Patients Treated With Methotrexate vs Biologic Agents

JAMA Dermatol.

Bronckers IMGJ, Paller AS, West DP, Lara-Corrales I, Tollefson MM, Tom WL, Hogeling M, Belazarian L, Zachariae C, Mahé E, Siegfried E, Blume-Peytavi U, Szalai Z, Vleugels RA, Holland K, Murphy R, Puig L, Cordoro KM, Lambert J, Alexopoulos A, Mrowietz U, Kievit W, Seyger MMB, Psoriasis Investigator Group, the Pediatric Dermatology Research Alliance, and the European Working Group on Pediatric Psoriasis

doi: 10.1001/jamadermatol.2019.4835.

COMMENTED

Psoriasis

Apremilast in psoriasis - a prospective real-world study

J Eur Acad Dermatol Venereol.

Vujic I, Herman R, Sanlorenzo M, Posch C, Monshi B, Rappersberger K, Richter L

doi: 10.1111/jdv.14598.

Psoriasis

Certolizumab Pegol for the Treatment of Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Pooled Analysis of Week 16 Data from 3 Randomized Controlled Trials

J Eur Acad Dermatol Venereol.

Blauvelt A, Reich K, Lebwohl M, Burge D, Arendt C, Peterson L, Drew J, Rolleri R, Gottlieb AB

doi: 10.1111/jdv.15258.

Psoriasis

Association of Patient Mental Health Status With the Level of Agreement Between Patient and Physician Ratings of Psoriasis Severity

JAMA Dermatol

Carr E, Mahil SK, Brailean A, Dasandi T, Pink AE, Barker JN, Rayner L, Turner MA, Goldsmith K, Smith CH

doi: 10.1001/jamadermatol.2020.5844

PsoriasisPsoriatic Arthritis

Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: Results of two phase III randomized, controlled trials

J Eur Acad Dermatol Venereol.

Thaçi D, Kimball A, Foley P, Poulin Y, Levi E, Chen R, Feldman SR

doi: 10.1111/jdv.13918.

PsoriasisFurther Publications Dermatology

Effectiveness and Safety of Apremilast in Biologic-naïve Patients With Moderate Psoriasis Treated in Routine Clinical Practice in Greece: the APRAISAL Study

J Eur Acad Dermatol Venereol

Ioannides D, Antonakopoulos N, Georgiou S, Chasapi V, Katsantonis I, Drosos A, Rigopoulos D, Antoniou C, Anastasiadis G, Bassukas I, Ioannidou D, Protopapa A, Neofotistou O, Krasagakis K, Aronis P, Papageorgiou M, Lazaridou E, Patsatsi A, Lefaki I, Roussaki-Schulze AV, Satra F, Anagnostopoulos Z, Papakonstantis M

doi: 10.1111/jdv.17392

Related content

Persistence of treatment with conventional systemic agents for patients with psoriasis: a real-world analysis of 73,168 new-users from the French National Health Insurance database (SNDS)

A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL)

An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

A Comparison of Psoriasis Severity in Pediatric Patients Treated With Methotrexate vs Biologic Agents

Apremilast in psoriasis - a prospective real-world study

Certolizumab Pegol for the Treatment of Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Pooled Analysis of Week 16 Data from 3 Randomized Controlled Trials

Association of Patient Mental Health Status With the Level of Agreement Between Patient and Physician Ratings of Psoriasis Severity

Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: Results of two phase III randomized, controlled trials

Effectiveness and Safety of Apremilast in Biologic-naïve Patients With Moderate Psoriasis Treated in Routine Clinical Practice in Greece: the APRAISAL Study